AI summary by TwinMind
Rick Doblin: Psychedelics | Lex Fridman Podcast #202
Lex Fridman
2h 36m 6s
Introduction to Psychedelics and MAPS
- Rick Doblin - founder/executive director of MAPS (Multidisciplinary Association for Psychedelic Studies)
- Psychedelic means "mind manifesting" - coined by Humphrey Osmond in dialogue with Aldous Huxley
- MAPS interprets psychedelic broadly: dreams, holotropic breathwork, hyperventilation, meditation
- Primary focus on drugs/medicines/spiritual tools/sacraments
Categories of Psychedelics
- Classic psychedelics: ego-dissolving, unitive states
- LSD, psilocybin, mescaline, ayahuasca, ibogaine, DMT
- MDMA: empathogen/entactogen - "touching within" or empathy
- Doesn't cause same ego dissolution as classics
- Brings material to surface, changes processing
- Marijuana: closer to classic psychedelics than MDMA
- Dreams as natural psychedelic state - everyone can relate
Mechanism: Bringing Things to Surface
- Brain as "reducing valve" (Aldous Huxley concept)
- Mind filters enormous information input, focuses on core needs (Maslow's hierarchy)
- Psychedelics dissolve ego control or strengthen self-acceptance (MDMA)
- Reveal suppressed material: traumas, conflicts, difficult emotions
- Not conjuring new experiences - revealing what's already within
- Sasha Shulgin: "having human experience that mescaline helps access" vs "mescaline experience"
Collective Unconscious and Memory
- Jungian collective unconscious - accessing information beyond personal temporal existence
- Wave resonances allowing access to other times/places through emotional resonances
- Holographic reality concept
- Cultural transmission more determinative than often credited
- Example: Terence McKenna's "machine elves" as cultural construct vs universal experience
Differences Between Psychedelics
Duration and Administration
- DMT (smoked): 10-15 minutes, rapid onset
- 5-MeO-DMT: very rapid when smoked
- Ayahuasca (oral DMT): couple hours
- LSD: 8-12 hours
- Psilocybin: 4-6 hours
- MDMA: similar to psilocybin, supplemental dosing used in research
Chemical Structure and Effects
- Mescaline: chemically most similar to MDMA (phenethylamine)
- Has warmth of MDMA, less ego-dissolving than other classics
- 1953 Army Chemical Warfare study: methamphetamine to mescaline spectrum, MDMA in middle
Religious/Cultural Context
- Some have thousands of years religious use (psilocybin mushrooms)
- Eleusinian Mysteries (1600 BC - 396 AD): longest mystery ceremonies, LSD-like substance
- 5-MeO-DMT claims of indigenous use are modern fabrications
- Rise of for-profit companies researching all types
Future Engineering of Psychedelics
- Buckminster Fuller prediction: technology miniaturization → telepathy
- Stan Grof's wife Brigitta: MDMA + 5-MeO-DMT combination
- Ego dissolution with underlying sense of safety/self-acceptance
- Personalized sequences of different drugs over time
- Structure-activity relationships still mysterious
- Sasha Shulgin's methodology: self-experimentation → wife → 12-person group → Leo Zeff (therapeutic use)
Historical Context: MK Ultra and Ken Kesey
- CIA program weaponizing psychedelics for interrogation, mind control
- Dosing people without consent, violating human rights
- Ken Kesey participated, later inspired hippie opposition to Vietnam War
- Unintended consequence: Grateful Dead emerged from acid tests
- Ted Kaczynski (Unabomber) allegedly part of MK Ultra at Harvard
- Context determines outcome - same drugs, different results
Timothy Leary and Harvard Research
- Nixon called him "most dangerous man in America"
- "Think for yourself, question authority"
- Harvard research 1960-1963: Good Friday Experiment, Concord Prison Experiment
- Good Friday: psilocybin in religious setting to produce mystical experience
- Concord Prison: reduce recidivism through mystical experiences
- Later revealed data manipulation in prison study
- Leary's approach: over-promised benefits, under-stated risks
- "Fuck the government... but I'm glad you're doing it" (to Rick)
MAPS Formation and Strategy (1986)
- Created after DEA criminalized MDMA in 1985
- Non-profit pharmaceutical company - first of its kind
- Strategy: Americans open to medicines for suffering
- Mission: mass mental health, spiritualizing humanity
- Einstein quote: "splitting of atom changed everything except mode of thinking"
- Two tracks: drug development + drug policy reform
MAPS Structure Evolution
- 2014: Created MAPS Public Benefit Corporation
- Non-profit owns 100% of pharma company
- Benefit corporation maximizes public benefit, not profit
- Data exclusivity (5-6 years) provides revenue stream
- Boston Consulting Group projects ~$750M profits during exclusivity period
- 130 employees: 1/3 non-profit (harm reduction, education), 2/3 benefit corp (research)
Phase Development Process
- Pre-clinical: Animal safety studies
- Phase 1: First human studies, safety in healthy volunteers
- Phase 2: Patient studies, design Phase 3, determine risks/benefits/measures
- Phase 3: Large-scale, multi-site, placebo-controlled studies proving safety/efficacy
Double-Blind Problem
- Classic challenge: psychedelics have obvious effects, hard to blind
- Rick's dissertation solution: low-dose vs full-dose MDMA
- Discovery: 75mg was effective dose (lower than expected 125mg)
- Low doses (25-50mg) created "anti-therapeutic effect" - stimulation without fear reduction
- FDA accepted therapy + inactive placebo vs therapy + full-dose MDMA design
- Independent rater pool of 20+ calibrated evaluators
Phase 3 PTSD Study Results (Nature Medicine, May 2021)
Study Design
- 90 participants (46 MDMA, 44 placebo)
- Chronic, severe PTSD patients
- Included previous suicide attempts (typically excluded)
- 15 sites (2 Israel, 2 Canada, 11 US)
- ~80 therapists trained
Statistical Results
- P-value: 0.0001 (1 in 10,000 chance of random result)
- Effect size: 0.91 placebo-subtracted, 2.1 within-group
- No effect by site (consistent across all locations)
- 67% MDMA group no longer had PTSD vs 32% placebo group at 2 months
Safety Findings
- Two suicide attempts during study - both in placebo group
- No suicide attempts in MDMA group
- Side effects: transitory, minor (sweating, jaw clenching, slight temperature increase)
- No neurocognitive decline
- Dissociative subtype (hardest to treat) did even better with MDMA
Mechanism
- MDMA reduces amygdala activity (fear processing)
- Increases prefrontal cortex activity (logical thinking)
- Increases connectivity between amygdala and hippocampus
- Enhances memory for trauma while reducing fear
- Helps process memories into long-term storage (past vs always about to happen)
Timeline for Access
- End of 2023: FDA approval expected for MDMA-assisted therapy for PTSD
- Expanded access: 50 people approved for compassionate use (starting ~2 months from interview)
- Off-label prescription: Doctors can prescribe for other conditions once approved
- 2035: Licensed legalization for personal growth predicted
- Decade of clinics: Thousands of psychedelic clinics rolling out post-approval
Other Promising Applications
- Psilocybin: Life-threatening illness, addiction, depression (breakthrough therapy status)
- Ibogaine: Opiate addiction, withdrawal management
- MDMA: Alcohol use disorder (Ben Sessa's research)
- Trauma underlying addiction: Common thread across substances
- Revolution in psychiatry predicted - returning therapists to treating individuals vs just prescribing
For-Profit Company Concerns
- Rise indicates success but creates profit maximization pressure
- Risk: minimizing therapy to reduce costs
- S-ketamine example: approved without therapy, results fade quickly
- Ketamine clinics discovering therapy improves outcomes
- Generic ketamine vs expensive S-ketamine
- MAPS leading by example with benefit corporation model
Advice to Young People
- Find combination of what world needs + what you need for survival
- Howard Thurman quote: "Find what makes you come alive - world needs people who have come alive"
- Beware trap of needing vast resources
- Separate happiness from accomplishments - focus on effort
- Build long-term relationships across perceived divides
- Be persistent - "once FDA/DEA figured out we're not going anywhere, progress started"
- 20-year plans not really that long
Philosophical Insights
- Don't need answers to big "why" questions
- Grateful for death - makes life precious
- Parents' quote: "Make up for brevity of life with intensity of life"
- One life is enough
- We're social creatures - making others happy, being made happy sufficient meaning
- Humanity in everyone - avoid us vs them thinking
- Example: Training police officer as MDMA therapist
